Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel

N. J. Polman, A. Oštrbenk, L. Xu, P. J. F. Snijders, C. J. L. M. Meijer, M. Poljak, D. A. M. Heideman, M. Arbyn

Department of Pathology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands; Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Unit of Cancer Epidemiology, Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium

ABSTRACT

Human papillomavirus (HPV) testing is increasingly being incorporated into cervical cancer screening. The Validation of HPV Genotyping Tests (VALGENT) is a framework designed to evaluate the clinical performance of various HPV tests relative to that of the validated and accepted comparator test in a formalized and uniform manner. The aim of this study was to evaluate the clinical performance of the HPV-Risk assay with samples from the VALGENT-3 panel and to compare its performance to that of the clinically validated Hybrid Capture 2 assay (HC2). The VALGENT-3 panel comprises 1,300 consecutive samples from women participating in routine cervical cancer screening and is enriched with 300 samples from women with abnormal cytology. DNA was extracted from original ThinPrep PreservCyt medium aliquots, and HPV testing was performed using the HPV-Risk assay by investigators blind to the clinical data. HPV prevalence was analyzed, and the clinical performance of the HPV-Risk assay for the detection of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) and CIN2 or worse (CIN2+) relative to the performance of HC2 was assessed. The sensitivity of the HPV-Risk assay for the detection of CIN3+ was similar to that of HC2 (relative sensitivity, 1.00; 95% confidence interval [CI], 0.95 to 1.05; \( P = 1.000 \)), but the specificity of the HPV-Risk assay was significantly higher than that of HC2 (relative specificity, 1.02; 95% CI, 1.01 to 1.04; \( P < 0.001 \)). For the detection of CIN2+, similar results were obtained, with the relative sensitivity being 0.98 (95% CI, 0.93 to 1.02; \( P = 0.257 \)) and the relative specificity being 1.02 (95% CI, 1.01 to 1.03; \( P < 0.001 \)). The performance of the HPV-Risk assay for the detection of CIN3+ and CIN2+ was noninferior to that of HC2, with all \( P \) values being \( \leq 0.006 \). In conclusion, the HPV-Risk assay demonstrated noninferiority to the clinically validated HC2 by the use of samples from the VALGENT-3 panel for test validation and comparison.

KEYWORDS

cervical cancer screening, human papillomavirus, HPV-Risk assay, Hybrid Capture 2, diagnostic test accuracy, clinical validation, VALGENT, HPV

Screening with human papillomavirus (HPV) testing provides better protection against cervical cancer and high-grade cervical intraepithelial neoplasia (CIN) than cytology-based screening (1, 2). Consequently, HPV testing is increasingly being incorporated into clinical protocols and cervical cancer screening guidelines. A substantial number of different HPV tests is currently available on the market (3); however, clinical validation of a test is required before its use for screening purposes.

The international validation guidelines described by Meijer et al. (4) have been used for the translation of HPV testing into clinical practice by setting standards for test performance and characteristics. However, the proper validation of HPV tests can be
problematic due to the difficulties with obtaining an appropriate set of clinical specimens. The Validation of HPV Genotyping Tests (VALGENT) framework facilitates the comparison and validation of HPV tests by providing a set of samples obtained from women attending routine screening enriched with cytologically abnormal samples (5–9). In order to allow comparison with other HPV tests, each VALGENT panel includes a comparator assay that is clinically validated for cervical cancer screening purposes.

The HPV-Risk assay is a real-time PCR-based assay that targets the E7 region of 15 (probable) high-risk HPV types and enables partial genotyping for HPV16 and HPV18. A previous evaluation of the HPV-Risk assay relative to the clinically validated comparator GP5+/6+/HP11001-PCR showed that its clinical performance and reproducibility met the international validation criteria for HPV tests for use in cervical cancer screening (10).

This study was performed to evaluate the clinical performance of the HPV-Risk assay for detection of high-grade CIN using the VALGENT-3 panel and to compare its performance to that of the clinically validated Hybrid Capture 2 assay (HC2) as a comparator test (4, 11).

RESULTS

HPV-Risk assay results. Of the 1,600 samples tested by the HPV-Risk assay, 30 (1.9%) samples were considered invalid for PCR amplification and were excluded from further analysis. HPV-Risk assay and HC2 results are shown in Table 1. Of the 1,570 (98.1%) valid results, 1,272 were from the screening population (including 9 CIN grade 2 [CIN2] and 11 CIN grade 3 or worse [CIN3+] cases) and 298 were from the enrichment population (including 36 CIN2 and 71 CIN3+ cases). Of 1,272 women in the screening population with valid HPV-Risk assay results, 133 (10.5%) women tested HPV positive. The prevalence of HPV16 and HPV18 was 2.6% (33/1,272) and 0.9% (12/1,272), respectively. Of 298 women in the enrichment population with valid HPV-Risk assay results, 205 (68.8%) women tested HPV positive. The prevalence of HPV16 and HPV18 was 27.2% (81/298) and 7.4% (22/298), respectively. For comparison, 159 (12.5%) women in the screening population and 214 (71.8%) women in the enrichment population tested HPV positive with HC2.

Clinical performance of the HPV-Risk assay. The absolute sensitivity and specificity of the HPV-Risk assay for the detection of CIN3+ and CIN grade 2 or worse (CIN2+) are shown in Table 2, both for the total study group (n = 1,316) and for women ≥30 years old (n = 1,088). Within the total study group, the sensitivity of the HPV-Risk assay for the detection of CIN3+ was 97.6% (95% confidence interval [CI], 91.5 to 99.7%) and the specificity was 89.0% (95% CI, 87.1 to 90.7%). For the detection of CIN2+, the sensitivity and specificity were 93.7% (95% CI, 88.0 to 97.2%) and 91.8% (95% CI, 90.1 to 93.3%), respectively. For women aged ≥30 years (n = 1,088), the sensitivity of the HPV-Risk assay for the detection of CIN3+ was 97.0% (95% CI, 89.5 to

---

**TABLE 1** HPV-Risk assay and HC2 results for screening and enrichment populations of VALGENT-3 panel

| Assay and result | Screening population | | | Enrichment population | | | Total | |
|------------------|----------------------|---|---|-----------------------|---|---|------------------|---|
|                  | n | %  | n | %  | n | %  | n | %  |
| HPV-Risk assay   | | | | | | | | |
| HPV positive     | 133 | 10.5 | 205 | 68.8 | 338 | 21.5 |
| HPV16 positive   | 33  | 2.6  | 81  | 27.2 | 114  | 7.3  |
| HPV18 positive   | 12  | 0.9  | 22  | 7.4  | 34  | 2.2  |
| HPV negative     | 1,139 | 89.5 | 93  | 31.2 | 1,232 | 78.5 |
| HC2              | | | | | | | | |
| HPV positive     | 159  | 12.5 | 214  | 71.8 | 373  | 23.8 |
| HPV-negative     | 1,113 | 87.5 | 84  | 28.2 | 1,197 | 76.2 |
| Total            | 1,272 | 100.0 | 298 | 100.0 | 1,570 | 100.0 |

*HPV, human papillomavirus; n, number of cases.*
99.6%) and the specificity was 91.8% (95% CI, 89.9 to 93.4%). For the detection of CIN2+ among women aged ≥30 years, the sensitivity and specificity of the HPV-Risk assay were 92.9% (95% CI, 85.8 to 97.1%) and 94.2% (95% CI, 92.6 to 95.6%), respectively.

The absolute sensitivities and specificities of HC2 for the detection of CIN3 and CIN2+ are shown in Table 2. Cross-tabulations of the results of the HPV-Risk assay and HC2 are shown in Table 3. The corresponding relative sensitivities of the HPV-Risk assay versus those of HC2 for the detection of CIN3+ and CIN2+ as well as the relative specificities of the HPV-Risk assay for the detection of cervical intraepithelial neoplasia grade 1 or lower (≤CIN1) are shown in Table 4. The sensitivity of the HPV-Risk assay for the detection of CIN3+ was the same as that of HC2 (97.6% versus 97.6%; relative sensitivity, 1.00; 95% CI, 0.95 to 1.05; $P_{\text{McN}} = 1.00$), but its specificity was significantly higher (89.0% versus 86.9%; relative specificity, 1.02; 95% CI, 1.01 to 1.04; $P_{\text{McN}} < 0.001$). Similar results were obtained for the detection of CIN2+ (i.e., a sensitivity of 93.7% versus 96.1% [relative sensitivity, 0.98; 95% CI, 0.93 to 1.02; $P_{\text{McN}} = 0.257$] and a specificity of 91.8% versus 89.9% [relative specificity, 1.02; 95% CI, 1.01 to 1.03; $P_{\text{McN}} < 0.001$]). The performance of the HPV-Risk assay was clinically

### Table 2: Sensitivity and specificity of HPV-Risk assay and HC2 for detection of CIN3+ and CIN2+.

| Assay, group studied, and CIN grade | Sensitivity | Specificity |
|-----------------------------------|-------------|-------------|
|                                  | n/N | %       | 95% CI    | n/N | %       | 95% CI    |
| HPV-Risk assay                   |     |         |           |     |         |           |
| Total group                      |     |         |           |     |         |           |
| CIN3+                            | 80/82 | 97.6 (91.5–99.7) | 1,098/1,234 | 89.0 (87.1–90.7) |
| CIN2+                            | 119/127 | 93.7 (88.0–97.2) | 1,092/1,189 | 91.8 (90.1–93.3) |
| Women ≥30 yr old                 |     |         |           |     |         |           |
| CIN3+                            | 64/66 | 97.0 (89.5–99.6) | 938/1,022 | 91.8 (89.9–93.4) |
| CIN2+                            | 91/98 | 92.9 (85.8–97.1) | 933/990 | 94.2 (92.6–95.6) |
| HC2                              |     |         |           |     |         |           |
| Total study group                | 80/82 | 97.6 (91.5–99.7) | 1,072/1,234 | 86.9 (84.6–88.7) |
| CIN3+                            | 122/127 | 96.1 (91.1–98.7) | 1,069/1,189 | 89.9 (88.1–88.7) |
| Women ≥30 yr old                 |     |         |           |     |         |           |
| CIN3+                            | 64/66 | 97.0 (89.5–99.6) | 918/1,022 | 89.8 (87.8–91.6) |
| CIN2+                            | 94/98 | 95.9 (89.9–98.9) | 916/990 | 92.5 (90.7–94.1) |

### Table 3: Comparison of HPV-Risk assay and HC2 for HPV detection stratified by clinical outcome.

| CIN grade | HPV-Risk assay result | Total study group | Women ≥30 yr old |
|-----------|-----------------------|-------------------|------------------|
|           |                       | Positive | Negative | Total | Positive | Negative | Total |
| CIN3+     | Positive              | 78       | 2        | 80    | 62       | 2        | 64    |
|           | Negative              | 2        | 0        | 2     | 2        | 0        | 2     |
|           | Total                 | 80       | 2        | 82    | 64       | 2        | 66    |
| CIN2+     | Positive              | 117      | 2        | 119   | 89       | 2        | 91    |
|           | Negative              | 5        | 3        | 8     | 5        | 2        | 7     |
|           | Total                 | 122      | 5        | 127   | 94       | 4        | 98    |
| ≤CIN1     | Positive              | 87       | 10       | 97    | 47       | 10       | 57    |
|           | Negative              | 33       | 1,059    | 1,092 | 27       | 906      | 933   |
|           | Total                 | 120      | 1,069    | 1,189 | 74       | 916      | 990   |

4HPV, human papillomavirus; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; ≤CIN1, cervical intraepithelial neoplasia grade 1 or lower, i.e., women with two consecutive negative cytology results (control group).
TABLE 4 Relative sensitivities for detection of CIN3+ and CIN2+ and relative specificities for detection of ≤CIN1 of HPV-Risk assay versus HC2

| Group studied and CIN grade | Relative sensitivity | Relative specificity | $P_{\text{McN}}$ | $P_{\text{ni}}$ |
|-----------------------------|---------------------|---------------------|------------------|----------------|
| Women of all ages            |                     |                     |                  |                |
| CIN3+                       | 1.00 (0.95–1.05)$^a$| 1.000               | 0.003            |                |
| CIN2+                       | 0.98 (0.93–1.02)    | 0.257               | 0.006            |                |
| ≤CIN1                       | 1.02 (1.01–1.03)    | <0.001              | <0.001           |                |
| Women ≥30 yr old            |                     |                     |                  |                |
| CIN3+                       | 1.00 (0.94–1.06)    | 1.000               | 0.007            |                |
| CIN2+                       | 0.97 (0.92–1.02)    | 0.257               | 0.010            |                |
| ≤CIN1                       | 1.02 (1.01–1.03)    | 0.005               | <0.001           |                |

$^a$HPV, human papillomavirus; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; ≤CIN1, cervical intraepithelial neoplasia grade 1 or lower, i.e., women with two consecutive negative cytology results (control group); $P_{\text{McN}}$, $P$ value by the McNemar test; $P_{\text{ni}}$, $P$ value for the noninferiority of HPV-Risk assay to HC2.

When we performed the analyses for women aged ≥30 years, results similar to those obtained for the total study group were obtained (Table 4). Relative sensitivity and specificity for the detection of CIN3+ in women aged ≥30 years were 1.00 (95% CI, 0.94 to 1.06; $P_{\text{McN}} = 1.000$) and 1.02 (95% CI, 1.01 to 1.04; $P_{\text{McN}} = 0.002$), respectively. Relative sensitivity and specificity for the detection of CIN2+ were 0.97 (95% CI, 0.92 to 1.02; $P_{\text{McN}} = 0.257$) and 1.02 (95% CI, 1.01 to 1.03; $P_{\text{McN}} = 0.005$), respectively. In women aged ≥30 years, the performance of the HPV-Risk assay was clinically noninferior to that of HC2 with respect to the sensitivity and specificity for the detection of CIN3+ ($P_{\text{ni}} = 0.007$ and $P_{\text{ni}} < 0.001$, respectively) and CIN2+ ($P_{\text{ni}} = 0.010$ and $P_{\text{ni}} < 0.001$, respectively).

**DISCUSSION**

In this study, we evaluated the clinical performance of the HPV-Risk assay for the detection of high-grade CIN and compared its performance to that of a clinically validated test (HC2) using samples from the VALGENT-3 panel. The results of this study show that the sensitivity of the HPV-Risk assay for the detection of CIN3+ and CIN2+ was comparable to that of HC2 and that it had a significantly higher specificity, both in the total study group and in women aged ≥30 years. The HPV-Risk assay showed a noninferior clinical performance compared to that of HC2.

Clinical validation studies of HPV tests are crucial because the HPV assays that are used for primary cervical cancer screening must ensure an optimal distinction between HPV infections associated with CIN2+/3+ and clinically irrelevant transient HPV infections (4). The current study, as an independent clinical validation in a different study cohort with a different clinically validated comparator test (HC2), further supports previously published clinical validation data for the HPV-Risk assay (10).

An advantage of the HPV-Risk assay, in comparison with other commercially available HPV assays, is that no specific laboratory equipment is needed since the HPV-Risk assay can run on different real-time PCR platforms and is compatible with various collection media and different DNA extraction procedures. Furthermore, the HPV-Risk assay can be performed reliably on self-sampled material, both lavage-based and brush-based material, in addition to physician-taken cervical scrape samples (10, 12, 13). The turnaround time of the HPV-Risk PCR method is about 1 h. However, the turnaround time of the total procedure, from sample collection to HPV test result, depends on the duration of the DNA extraction method that is used. Finally, the HPV-Risk assay targets a conserved region within the E7 open reading frame of the respective high-risk HPV types. A recent study has shown that the E7 region of HPV16, noninferior to that of HC2 with respect to sensitivity and specificity for the detection of CIN3+ ($P$ value for the noninferiority of the HPV-Risk assay to HC2 [$P_{\text{ni}}$] = 0.003 and $P_{\text{ni}} < 0.001$, respectively) and also for CIN2+ ($P_{\text{ni}} = 0.006$ and $P_{\text{ni}} < 0.001$, respectively).

Values in parentheses are 95% confidence intervals.
The strength of this study is the large sample set from the VALGENT-3 framework, which makes it possible to evaluate the clinical performance of various HPV assays compared to that of the validated and accepted comparator test (HC2) in a formalized and uniform manner. In addition, a network of test comparisons, which can later be pooled in multiple-testing meta-analysis, can be developed (4, 5, 11). Another strength is that testing by the HPV-Risk assay was performed by investigators completely blind to the clinical data and cytology findings. Furthermore, in accordance with the VALGENT framework criteria, aliquots of original, nonisolated cervical scrape material were sent to the test laboratory; therefore, not only the assay itself but also the entire laboratory process from sample processing to the HPV test result was evaluated. Finally, in VALGENT-3, women were managed on the basis of cytology and HPV screening test results, whereas in a previous VALGENT round, VALGENT-2, detection of (pre-)cancerous lesions was triggered only through cytology (6–9). Therefore, the VALGENT-2 panel might have included a circumstantial advantage for sensitivity and a disadvantage for specificity. On the other hand, a relatively short active follow-up period in VALGENT-3 (12 to 48 months) may be considered a limitation. However, since HC2 was used as a comparator test that was validated through randomized trials with follow-up over 8 years, its cross-sectional accuracy is considered sufficient for validation. Nevertheless, VALGENT-3 results will soon most likely be linked to the outcomes of subsequent cervical cancer screening rounds (continuous passive follow-up through the Slovenian National Cervical Cancer Screening Registry and National Cancer Registry), which will provide information on long-term safety.

In conclusion, the HPV-Risk assay has a high sensitivity and a high specificity for the detection of CIN3+ and CIN2+ and has a demonstrated noninferiority to the clinically validated HC2. Results from this study provide additional evidence that the HPV-Risk assay can be considered clinically validated and therefore can be safely used for primary cervical cancer screening.

MATERIALS AND METHODS

VALGENT-3 panel. The VALGENT-3 panel was collated in Slovenia (5). Ethical approval was obtained from the Medical Ethics Committee of the Republic of Slovenia (consent numbers 83/11/09 and 109/08/12). The panel is standardized, comprising 1,300 consecutive samples from women participating in the organized national cervical cancer screening program with more than 70% coverage (screening population), enriched with 300 samples from women with abnormal cytology (enrichment population). The characteristics of the two study populations are shown in Table 5.

Cervical scrape samples from the screening population were collected from December 2009 to August 2010, and samples from the enrichment population were collected from January 2014 to May 2015. All samples were collected in ThinPrep PreservCyt medium (Hologic, Bedford MA, USA) according to European Union guidelines (15). Samples were transported to the University of Ljubljana (Ljubljana, Slovenia) weekly. Several aliquots were prepared from each cervical specimen. One aliquot was used for HC2 testing, and the remaining aliquots were immediately stored at −70°C and later sent to participating laboratories for HPV testing. HC2 was performed according to the manufacturer’s instructions (Qiagen, Gaithersburg MD, USA) at the University of Ljubljana (Ljubljana, Slovenia) during the period from December 2009 to August 2010 (16). HC2 testing was performed within 2 weeks after sample collection. Briefly, HC2 uses a cocktail of captured RNA probes to detect 13 high-risk HPV types (i.e., HPV16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, and −68). The probes hybridize with viral DNA, and the captured HPV RNA/DNA hybrids are identified by a secondary capture system that yields a light signal. The intensity of the light signal can be semiquantitatively related to the viral load (17–19).

Management of the women was based on the results of cytology and HPV testing (by HC2 and the Abbott RealTime High Risk HPV test), as previously described in detail (16). Women with atypical-squamous-cell (the possibility of a high-grade squamous intraepithelial lesion cannot be excluded) (ASC-H) or atypical-glandular-cell (AGC) cytology or worse were invited for colposcopy, according to the criteria of the Slovenian National Cervical Cancer Screening Program and European Union guidelines for quality assurance for cervical cancer screening (3, 16, 20). In addition, women who tested positive for HPV16 or HPV18 were invited for colposcopy irrespective of their cytology result. Women who tested
HPV-non-16/18 positive were invited for either colposcopy or a control visit after 6 to 12 months, at the physician’s discretion. During colposcopy, biopsy specimens were taken from any regions suspicious for CIN. Histological samples were classified as CIN grade 0, 1, 2, or 3 or as invasive cancer (21, 22).

For testing with the HPV-Risk assay, ThinPrep aliquots were transported to the VU University Medical Center (Amsterdam, The Netherlands) in June 2016. Extraction of DNA from the ThinPrep aliquots was performed using an automated extraction system (Macherey-Nagel, Duren, Germany) during the period from August to December 2016, with subsequent HPV-Risk assay testing being performed according to the manufacturer’s instructions (Self-screen BV, Amsterdam, The Netherlands). Accordingly, the time between sample collection and HPV-Risk assay testing was approximately 7 years. The HPV-risk assay targets the E7 region of 15 (probably) high-risk HPV types. Detection is based on hydrolysis probes with 3 spectrally unique fluorescent dyes, providing genotype information for HPV16 and HPV18 and a pooled detection of the 13 other HPV types (i.e., HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68) (10). The fourth channel enables detection of the human β-globin gene using a probe labeled with a different fluorescent dye, intended for assessment of the sample quality control (internal control) and potential inhibition. Samples were considered HPV positive when the threshold cycle \( (CT) \) values for HPV16, HPV18, and/or other HPV types were \( \leq 36 \). If no HPV signals were obtained and the \( CT \) value for the \( β\)-globin target was \( >33 \), samples were considered HPV negative. Samples were considered invalid when the \( CT \) value for HPV was \( >36 \) and that for \( β\)-globin was \( >33 \).

All HPV testing was performed by investigators blind to the clinical data and cytology findings. Results obtained by testing by both HPV assays were sent to the Unit of Cancer Epidemiology, Scientific Institute of Public Health (Brussels, Belgium), where analysis and evaluation of the data were performed.

**Statistical analysis.** On the basis of the HPV-Risk assay results, the overall prevalence of high-risk HPV infection and the type-specific prevalence of HPV16 and HPV18 infection were assessed in the screening population of 1,300 women. For clinical validation, women with histologically confirmed CIN2, CIN3, and cervical cancer within 48 months after sample collection were classified as having high-grade disease (disease group). Women with two consecutive negative cytology results (at enrollment and at 12 to 48 months of follow-up) were classified as having no evidence of disease (control group). The clinical performance of the HPV-Risk assay for the detection of both CIN3 (primary endpoint) and CIN2 (secondary endpoint) was assessed in the total study group and in women aged \( \geq 30 \) years, and the clinical performance of the HPV-Risk assay was compared to the clinical performance of HC2 as the

### TABLE 5

| Characteristic | Screening population | Enrichment population | Total |
|----------------|----------------------|-----------------------|-------|
| Mean (range) age (yr) | 39 (21–64) | 37 (20–77) | 39 (20–77) |
| No. (%) of women age: | | | |
| \( \geq 30 \) yr | 1,085 (83.5) | 221 (73.7) | 1,306 (81.6) |
| <30 yr | 215 (16.5) | 79 (26.3) | 294 (18.4) |
| No. (%) of women with the following cytology: | | | |
| Normal cytology | 1,238 (95.2) | 0 (0.0) | 1,238 (77.4) |
| ASC-US | 31 (2.4) | 100 (33.3) | 131 (8.2) |
| LSIL | 13 (1.0) | 100 (33.3) | 113 (7.1) |
| ASC-H | 3 (0.2) | 0 (0.0) | 3 (0.2) |
| HSIL | 14 (1.1) | 100 (33.3) | 114 (7.1) |
| AGC | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| No. (%) of women with the following histology: | | | |
| No histology | 1,266 (97.4) | 80 (26.7) | 1,346 (84.1) |
| Normal histology | 4 (0.3) | 73 (24.3) | 77 (4.8) |
| CIN1 | 10 (0.8) | 40 (13.3) | 50 (3.1) |
| CIN2 | 9 (0.7) | 36 (12.0) | 45 (2.8) |
| CIN3 (including CIS) | 11 (0.8) | 69 (23.0) | 80 (5.0) |
| SCC | 0 (0.0) | 1 (0.3) | 1 (0.1) |
| Adenocarcinoma | 0 (0.0) | 1 (0.3) | 1 (0.1) |
| Total | 1,300 (100.0) | 300 (100.0) | 1,600 (100.0) |

*The screening population included 1,300 subjects, and the enrichment population included 300 subjects.

ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; ASC-H, atypical squamous cells (the possibility of a high-grade squamous intraepithelial lesion cannot be excluded); HSIL, high-grade squamous intraepithelial lesion; AGC, atypical glandular cells; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; SCC, squamous cell carcinoma.

HPV-non-16/18 positive were invited for either colposcopy or a control visit after 6 to 12 months, at the physician’s discretion. During colposcopy, biopsy specimens were taken from any regions suspicious for CIN. Histological samples were classified as CIN grade 0, 1, 2, or 3 or as invasive cancer (21, 22).

**HPV-Risk assay.** For testing with the HPV-Risk assay, ThinPrep aliquots were transported to the VU University Medical Center (Amsterdam, The Netherlands) in June 2016. Extraction of DNA from the ThinPrep aliquots was performed using an automated extraction system (Macherey-Nagel, Duren, Germany) during the period from August to December 2016, with subsequent HPV-Risk assay testing being performed according to the manufacturer’s instructions (Self-screen BV, Amsterdam, The Netherlands). Accordingly, the time between sample collection and HPV-Risk assay testing was approximately 7 years. The HPV-risk assay targets the E7 region of 15 (probably) high-risk HPV types. Detection is based on hydrolysis probes with 3 spectrally unique fluorescent dyes, providing genotype information for HPV16 and HPV18 and a pooled detection of the 13 other HPV types (i.e., HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68) (10). The fourth channel enables detection of the human β-globin gene using a probe labeled with a different fluorescent dye, intended for assessment of the sample quality control (internal control) and potential inhibition. Samples were considered HPV positive when the threshold cycle \( (CT) \) values for HPV16, HPV18, and/or other HPV types were \( \leq 36 \). If no HPV signals were obtained and the \( CT \) value for the β-globin target was \( >33 \), samples were considered HPV negative. Samples were considered invalid when the \( CT \) value for HPV was \( >36 \) and that for β-globin was \( >33 \).

All HPV testing was performed by investigators blind to the clinical data and cytology findings. Results obtained by testing by both HPV assays were sent to the Unit of Cancer Epidemiology, Scientific Institute of Public Health (Brussels, Belgium), where analysis and evaluation of the data were performed.
standard comparator assay. Sensitivity and specificity were calculated from cross-tabulation of the test results with exact 95% confidence intervals (CIs).

Relative sensitivities (ratios of the sensitivity of one test to the sensitivity of another test) and relative specificities (ratios of the specificity of one test to the sensitivity of another test) with 95% CIs were calculated. The McNemar (McN) test was applied to assess differences between matched proportions. A $P_{\text{McN}}$ value of $>0.05$ indicated that the sensitivity or specificity of the HPV-Risk assay was not significantly different from that of HC2. Finally, the noninferiority (ni) of the HPV-Risk assay to HC2 was assessed, according to the international validation criteria (4, 23). In order to demonstrate noninferiority, the sensitivity of the HPV-Risk assay had to be at least 90% and the specificity had to be at least 98% compared to the results of HC2. A $P_{\text{ni}}$ value of $<0.05$ indicated that the sensitivity or specificity of the HPV-Risk assay was not significantly lower than that of HC2.

ACKNOWLEDGMENTS

We thank S. Doorn and M. van der Salm for excellent technical assistance and Self-screen B.V. for supplying the HPV-Risk assay kits.

N.J.P., A.O., L.X., P.J.F.S., C.J.L.M.M., M.P., and M.A. were supported by the COHEAHR Network, coordinated by the VU University Medical Center (Amsterdam, The Netherlands) and funded by the 7th Framework Programme of the European Commission (Brussels, Belgium), grant Health-F3-2013-603019.

VALGENT is a researcher-induced study network initiated by the Scientific Institute of Public Health (Brussels, Belgium) with the aim of performing independent evaluations of HPV assays in collaboration with academic partners (5–9). Manufacturers can have their test assessed through VALGENT when the costs for logistics and statistical analysis are covered and test kits/equipment are delivered to a recognized academic laboratory and if independent reporting is assured. The researchers of the Scientific Institute of Public Health did not receive personal advantages from the manufacturers of the HPV tests included in VALGENT. The Scientific Institute of Public Health did not receive any funding for the current evaluation of the HPV-Risk assay. P.J.F.S. has been on the speakers’ bureaus of Roche Diagnostics, Gen-Probe, Abbott, Qiagen, and Seegene and has been a consultant for Crucell B.V. C.J.L.M.M. has received speaker’s fees from GSK, Qiagen, SPMSD/Merck, Roche Diagnostics, Menarini, and Seegene, has occasionally served on the scientific advisory board (expert meeting) of GSK, Qiagen, SPMSD/Merck, Roche, and Gentecil, has on occasion been a consultant for Qiagen and Gentecil, and has a small number of shares in Qiagen. Until April 2016, C.J.L.M.M. was minority shareholder of Diassay B.V., and until 2014 he held a small number of certificates of shares in Delphi Biosciences, which went into receivership in 2014. D.A.M.H. occasionally serves on the scientific advisory board of Pfizer and has been on the speakers’ bureau of Qiagen. P.J.F.S., C.J.L.M.M., and D.A.M.H. are minority stakeholders of Self-screen B.V., a spin-off company of the VU University Medical Center, and since September 2017, C.J.L.M.M. has been a part-time director of Self-screen B.V. Self-screen B.V. holds patents related to the work.

REFERENCES

1. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ongilvie G, Koliopoulos G, Naucler P, Sankaranarayan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5):F88–F99. https://doi.org/10.1016/j.vaccine.2012.06.095.

2. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ. International HPV Screening Working Group. 2014. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:S24–S32. https://doi.org/10.1016/S0140-6736(13)62218-7.

3. Poljak M, Koçjan BJ, Ostrenk A, Seme K. 2016. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol 76(Suppl 1):S3–S13. https://doi.org/10.1016/j.jcv.2015.10.023.

4. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Deech FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:S16–S20. https://doi.org/10.1002/ijc.24010.

5. Arbyn M, Depuydt C, Benoy I, Rogers J, Cuschieri K, Schmitt M, Pawlita M, Geraets D, Heard I, Gheit T, Tommasino M, Poljak M, Bonde J, Quint W. 2016. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol 76(Suppl 1):S14–S21. https://doi.org/10.1016/j.jcv.2015.09.014.

6. Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M. 2014. Clinical evaluation of a Luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol 52:3996–4002. https://doi.org/10.1128/JCM.01962-14.

7. Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M. 2015. Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol 53:3272–3279. https://doi.org/10.1128/JCM.01366-15.

8. Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W, Arbyn M. 2016. Performance of a cartridge-based assay for detection of clinically significant human papillomavirus (HPV) infection: lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol 54:2337–2342. https://doi.org/10.1128/JCM.00897-16.
9. Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M. 2016. Clinical and analytical performance of the PapilloCheck HPV-screening assay using the VALGENT framework. J Clin Virol 81:6–11. https://doi.org/10.1016/j.jcv.2016.05.004.

10. Hesselink AT, Berkhof J, van der Salm ML, van Splunter AP, Geelen TH, van Kemenade FJ, Bleeker MG, Heideman DA. 2014. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol 52:890–896. https://doi.org/10.1128/JCM.03195-13.

11. Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, Poljak M. 2015. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 21:817–826. https://doi.org/10.1016/j.cmi.2015.04.015.

12. Arbyn M, Castle PE. 2015. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev 24:769–772. https://doi.org/10.1158/1055-9965.EPI-14-1417.

13. Arbyn M, Verdoordt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanens P, Anttila A. 2014. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 15:172–183. https://doi.org/10.1016/S1470-2045(13)70570-9.

14. Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M. 2017. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell 170:1164–1174 e6. https://doi.org/10.1016/j.cell.2017.08.001.

15. Arbyn M, Herbert A, Schenck U, Nieminen P, Jordan J, McGoogan E, Patrick J, Bergeron C, Baldauf JJ, Klinkhamer P, Bulten J, Martin-Hirsch P. 2007. European guidelines for quality assurance in cervical screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 18:133–139. https://doi.org/10.1111/j.1365-2303.2007.00464.x.

16. Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanens P, Bokal EV, Jancar N, Klavz I. 2011. Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test to the performance of Hybrid Capture 2 in population-based cervical cancer screening. J Clin Microbiol 49:1721–1729. https://doi.org/10.1128/JCM.00012-11.

17. Lorincz AT. 1997. Methods of DNA hybridization and their clinical applicability to human papillomavirus detection, p 325–327. In Franco E, Monsonego J (ed), New developments in cervical cancer screening and prevention. Blackwell Science, Oxford, United Kingdom.

18. Lorincz AT. 1996. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 22:629–636. https://doi.org/10.1111/j.1447-0756.1996.tb01081.x.

19. Poljak M, Brencic A, Seme K, Vince A, Marin U. 1999. Comparative evaluation of first- and second-generation Digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 37:796–797.

20. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P, Prendiville W. 2008. European guidelines for clinical management of abnormal cervical cytology, part 1. Cytopathology 19:342–354. https://doi.org/10.1111/j.1365-2303.2008.00623.x.

21. Anderson B. 1995. Premalignant and malignant squamous lesions of the cervix, p 273–322. In Fox H (ed), Haines and Taylor obstetrical and gynaecological pathology. Churchill Livingstone, Edinburgh, United Kingdom.

22. Richart RM. 1973. Cervical intraepithelial neoplasia. Pathol Annu 8:301–328.

23. Tang NS, Tang ML, Chan IS. 2003. On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 22:1217–1233. https://doi.org/10.1002/sim.1213.